Royal Bank of Canada’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Royal Bank of Canada’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.89M	Buy	261,376 +65,099	+33%	+$524K	﹤0.01%	3134
2025 Q4	$1.48M	Sell	196,277 -232,527	-54%	-$1.43M	﹤0.01%	3350
2025 Q3	$2.53M	Buy	428,804 +220	+0.1%	+$1.2K	﹤0.01%	3204
2025 Q2	$2.47M	Buy	428,584 +85,756	+25%	+$329K	﹤0.01%	3128
2025 Q1	$1.13M	Buy	342,828 +59,683	+21%	+$206K	﹤0.01%	3376
2024 Q4	$898K	Buy	283,145 +11,858	+4%	+$35.1K	﹤0.01%	3632
2024 Q3	$714K	Buy	271,287 +5,543	+2%	+$14.6K	﹤0.01%	3819
2024 Q2	$686K	Buy	+265,744	New	+$739K	﹤0.01%	3764

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Royal Bank of Canada's EPRX Position: Q1 2026 in Review

Royal Bank of Canada increased its Eupraxia Pharmaceuticals (EPRX) stake by 33% in Q1 2026, buying an estimated $524K and bringing the position to 261,376 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3134.

Royal Bank of Canada first reported a position in EPRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.53M in Q3 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

Royal Bank of Canada held 261,376 shares of Eupraxia Pharmaceuticals worth $1.89M as of Q1 2026.
Royal Bank of Canada bought 65,099 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $524K.
Eupraxia Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3134 holding.
Royal Bank of Canada first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Royal Bank of Canada's Eupraxia Pharmaceuticals position peaked at $2.53M in Q3 2025.
54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.